Immunocore Holdings PLC ADR
Slēgts
32.4 -2.94
Pārskats
Akcijas cenas izmaiņa
24h
Min
32.4
Max
32.84
Ienākumi | -14M -786K |
|---|---|
Pārdošana | 9.3M 116M |
EPS | -0.02 |
Peļņas marža | -0.678 |
Darbinieki | 524 |
EBITDA | -13M 3.6M |
Nākamie ieņēmumi | 2026. g. 5. nov. |
|---|
Tirgus kapitalizācija | 211M 1.9B |
|---|---|
Iepriekšējā atvēršanas cena | 35.34 |
Iepriekšējā slēgšanas cena | 32.4 |
Immunocore Holdings PLC ADR Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Saistītās ziņas
Salīdzinājums
Cenas izmaiņa
Immunocore Holdings PLC ADR Prognoze
Finanšu rādītāji
Pārdošanas un administrēšanas izmaksas
Darbības izmaksas
Peļņa pirms nodokļu nomaksas
Pārdošana
Pārdošanas maksa
Bruto peļņa no pārdošanas
Procentu izdevumi par parādu
EBITDA
Pamatdarbības peļņa
$
Par Immunocore Holdings PLC ADR
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.